These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27749979)

  • 1. Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.
    Qu Y; Guo Y; Li T; Ye Q; Sun C; Wang L; Yang B
    J Gastroenterol Hepatol; 2017 Apr; 32(4):740-748. PubMed ID: 27749979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
    Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
    Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
    Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
    Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
    Xue W; Liu K; Qiu K; Shen Y; Pan Z; Hu P; Peng M; Chen M; Ren H
    Int J Infect Dis; 2019 Jun; 83():56-63. PubMed ID: 30959250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
    Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
    Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
    Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
    World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.
    Lutchman G; Nguyen NH; Chang CY; Ahmed A; Daugherty T; Garcia G; Kumari R; Gupta S; Doshi D; Nguyen MH
    Aliment Pharmacol Ther; 2016 Oct; 44(7):738-46. PubMed ID: 27506182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.
    Faisal N; Bilodeau M; Aljudaibi B; Hirch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Lilly LB
    Exp Clin Transplant; 2019 Feb; 17(1):59-63. PubMed ID: 29619910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
    Pungpapong S; Aqel B; Leise M; Werner KT; Murphy JL; Henry TM; Ryland K; Chervenak AE; Watt KD; Vargas HE; Keaveny AP
    Hepatology; 2015 Jun; 61(6):1880-6. PubMed ID: 25722203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
    Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
    Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
    Chuang WL; Chien RN; Peng CY; Chang TT; Lo GH; Sheen IS; Wang HY; Chen JJ; Yang JC; Knox SJ; Gao B; Garrison KL; Mo H; Pang PS; Hsu YC; Hu TH; Chu CJ; Kao JH
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1323-9. PubMed ID: 26841930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.
    Ren XD; Fu X; He YQ; Li CY; Guo M; Qiao M
    Medicine (Baltimore); 2022 Oct; 101(42):e31183. PubMed ID: 36281168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
    Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.